Characteristics and Treatment Outcomes among HIV‐Infected Individuals in the Australian Trial in Acute Hepatitis C
Open Access
- 1 March 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 48 (5) , 650-658
- https://doi.org/10.1086/596770
Abstract
Background. The Australian Trial in Acute Hepatitis C (ATAHC) is a National Institutes of Health-funded prospective cohort study of the natural history and efficacy of treatment in individuals with recently acquired hepatitis C. Enrollment is open to both human immunodeficiency virus (HIV)-infected and -uninfected individuals. The aim of this article was to evaluate characteristics and virological outcomes among HIV-infected individuals enrolled in ATAHC. Methods. Eligibility criteria included the first positive result of testing for anti-hepatitis C virus (HCV) antibody within 6 months and either clinical hepatitis diagnosed within the past 12 months or documented anti-HCV seroconversion within the past 24 months. Results. Of the initial 103 patients enrolled, 27 (26%) were HIV infected. HIV-infected patients were more likely to be older, to have HCV genotype 1 infection and high levels of HCV RNA at baseline than were HCV-monoinfected patients. Sexual acquisition accounted for the majority (56%) of HCV infections among HIV-infected patients, compared with only 8% of HCV-monoinfected patients. The median duration from estimated HCV infection to treatment was 30 weeks. Treatment with 24 weeks of pegylated interferon and ribavirin resulted in rates of undetectability of HCV RNA of 95%, 90%, and 80% at weeks 12, 24, and 48, respectively. Undetectability at week 4 was achieved in 44% of patients and yielded positive and negative predictive values for sustained virological response of 100% and 33%, respectively. Conclusions. Significant differences were demonstrated between HIV-infected and HIV-uninfected individuals enrolled in ATAHC. Treatment responses among HIV-infected individuals with both acute and early chronic infection are encouraging and support regular HCV screening of high-risk individuals and early treatment for recently acquired HCV infection.Keywords
This publication has 28 references indexed in Scilit:
- Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase?Sexually Transmitted Infections, 2004
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected PatientsNew England Journal of Medicine, 2004
- Peginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected PersonsNew England Journal of Medicine, 2004
- Acute hepatitis C in HIV‐infected men who have sex with menHIV Medicine, 2004
- Surveillance for newly acquired hepatitis C in Australia.Journal of Gastroenterology and Hepatology, 2004
- Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studiesJournal of Antimicrobial Chemotherapy, 2003
- Early Virologic Response to Treatment With Peginterferon Alfa–2B Plus Ribavirin in Patients With Chronic Hepatitis CHepatology, 2003
- Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance1 1The Bundesministerium für Bildung und Forschung and the European Union, as sponsors of the study, had no role in study design, data collection, analysis, or interpretation or in the writing and the decision to submit the report for publication.Gastroenterology, 2003
- Treatment of Acute Hepatitis C with Interferon Alfa-2bNew England Journal of Medicine, 2001
- Influence of Human Immunodeficiency Virus Infection on the Course of Hepatitis C Virus Infection: A Meta‐AnalysisClinical Infectious Diseases, 2001